Alpha MED Scientific

Alpha MED Scientific operates in the specialized research-instrument segment for in vitro microelectrode-array electrophysiology. Alpha MED Scientific’s differentiation is its broad, internally connected product range: amplifiers, MED Probes, multi-well systems, stimulation capabilities, software, and experimental accessories are organized around one platform. The technology targets both recording and stimulation, with planar electrodes, reported low impedance of 10 kΩ at 1 kHz, and configurations ranging from entry-level 16-channel acquisition to multi-sample and multi-well workflows. Applications extend beyond neuroscience into cardiomyocyte research, safety pharmacology, toxicology, and drug screening. Its acquisition by SCREEN Holdings in 2016 provides a strategic ownership context distinct from a venture-backed growth model.

Alpha MED Scientific was incorporated on Sep 18, 2009 and has built its business around the MED64 microelectrode-array platform rather than a sequence of publicly documented venture-financed expansions. The clearest inflection point was the Feb 4, 2016 acquisition by SCREEN Holdings, which established a corporate ownership relationship while preserving Alpha MED Scientific’s product and support focus. The portfolio indicates incremental breadth across research workflows: MED64-Basic and MED64-Entry address lower-complexity use cases, while Quad II, Allegro, Plex 4/8, and Presto support higher-throughput, multi-probe, multi-sample, or multi-well experiments. The platform’s application range also expanded from conventional electrophysiology toward stem-cell-derived neurons and cardiomyocytes, pharmaceutical response testing, toxicology, and safety pharmacology. There are no disclosed funding rounds, valuation figures, employee-growth statistics, or post-2019 product-launch records to quantify acceleration. The available trajectory therefore suggests sustained specialization and product-line extension, with strategic backing from SCREEN Holdings, rather than a clearly measurable high-growth startup pattern.